Vimarsana
Biggest News Aggregation in the World

Markc Schneyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Markc Schneyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Markc Schneyer Today - Breaking & Trending Today

Rafferty Asset Management LLC Acquires 91,317 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Vimarsana News

Rafferty Asset Management LLC Acquires 91,317 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Rafferty Asset Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 427,930 shares of the biopharmaceutical company’s stock after purchasing an additional 91,317 shares during the period. Rafferty […]

Rafferty Asset Management LLC Acquires 91,317 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Vimarsana News

Rafferty Asset Management LLC Acquires 91,317 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Rafferty Asset Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 427,930 shares of the biopharmaceutical company’s stock after purchasing an additional 91,317 shares during the period. Rafferty […]

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Price Target at $28.94 - Vimarsana News

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Price Target at $28.94

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month […]

ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 1-Year Low at $14.60 - Vimarsana News

ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 1-Year Low at $14.60

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $14.60 and last traded at $14.68, with a volume of 628880 shares. The stock had previously closed at $15.09. Analyst Upgrades and Downgrades Several analysts recently weighed in on […]

Source: wkrb13.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 52-Week Low at $14.60 - Vimarsana News

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 52-Week Low at $14.60

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $14.60 and last traded at $14.68, with a volume of 628880 shares traded. The stock had previously closed at $15.09. Analysts Set New Price Targets Several brokerages have […]